Shopping Cart (0)
My Account

Shopping Cart
3 for 2 Offer SELECTBIO Conferences Regenerative Medicine & Cell Therapy Asia 2023Organoids and Organ-on-a-Chip Asia 2023Lab-on-a-Chip and Microfluidics Asia 2023Flow Chemistry Asia 2023Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023ePoster Award Prize

Methods to Detect and Quantify Circulating Cell-Free DNA: Opportunities for Liquid Biopsy Development

Theresa Zhang, Vice President, Research Services, Personal Genome Diagnostics

Dr. Zhang joined PGDx from Merck Research Laboratories, where she held positions of increasing responsibility for predictive biomarker identification and clinical implementation for oncology compounds for over a decade. During her tenure at Merck, Dr. Zhang oversaw the development of specially designed CLIA assays for use in cancer clinical trials and advanced a number of candidate biomarkers for clinical validation. She also managed multiple external collaborations. Dr. Zhang received BS degrees from Peking University and Bridgewater College and a PhD from the University of Virginia. She completed a Postdoctoral Fellowship in bioinformatics at Cold Spring Harbor Laboratories. Dr. Zhang is a co-author of numerous scientific publications and a frequent presenter at scientific meetings.

Theresa Zhang Image

Sonya Parpart-Li, Manager Lab Operation, Personal Genome Diagnostics

Sonya Parpart-Li received her Ph.D. in Tumor Biology from Georgetown University as part of a Graduate Partnership Program with the National Institutes of Health. Her dissertation work focused on deciphering heterogeneity among hepatocellular carcinoma (HCC) patients at the molecular level using microarrays, functional assays and bioinformatics analysis to assess gene expression and methylation status. In 2014 she joined Personal Genome Diagnostics (PGDx) as part of their R&D team where she has developed next-generation sequencing based cancer diagnostics to address tumor heterogeneity and to detect clinically actionable genetic mutations in a multitude of cancer types. More recently, she helped launch a comprehensive noninvasive diagnostic test for detection of sequence mutations and structural alterations in circulating tumor DNA shed into the blood.

Sonya Parpart-Li Image